👪

Inheritance

3

Autosomal Dominant HP:0000006

Dominant disease is typically caused by gain-of-function alleles of GUCA1A or GUCY2D that leave retinal guanylate cyclase inappropriately active.

autosomal dominant inheritance

Show evidence (1 reference)

PMID:15790869 SUPPORT Human Clinical

"Affected family members harbored a C-->T transition in exon 4 of the GCAP1 gene, resulting in an L151F missense mutation affecting the"

Documents segregation of the GCAP1 allele with affected status in a pedigree studied for autosomal dominant cone-rod dystrophy.

Autosomal Recessive HP:0000007

Recessive disease arises from biallelic loss of function in the cone phototransduction machinery, including PDE6C and the CNGA3/CNGB3 channel subunits.

autosomal recessive inheritance

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"Genetic testing identified two heterozygous PDE6C variants: a likely pathogenic frameshift variant (c.2304_2305delAA; p.Asp770Ter), predicted to result in premature truncation of the protein, and a"

Documents biallelic PDE6C variants in an affected individual, the transmission pattern this inheritance mode asserts.

X-Linked HP:0001417

X-linked cone and cone-rod dystrophy is caused by RPGR variants, particularly distal truncating variants in the ORF15 repeat region that impair glutamylation of the RPGR protein.

X-linked inheritance

Show evidence (1 reference)

PMID:41481301 SUPPORT Human Clinical

"Recent insights into impaired glutamylation caused by distal truncating variants in RPGR ORF15 and its association with the cone-dominated phenotype have provided the first molecular evidence of a genotype-phenotype correlation in male individuals with X-linked RPGR-related retinal dystrophy"

Establishes the X-linked RPGR ORF15 genotype-phenotype correlation in hemizygous males - the correct gene, species and mode of inheritance.

◆

Subtypes

2

Cone dystrophy with supernormal rod response (KCNV2)

KCNV2-associated retinopathy, distinguished by a pathognomonic delayed supernormal rod b-wave with a squared a-wave on the dark-adapted electroretinogram. Onset is much earlier than typical progressive cone dystrophy, with all patients symptomatic before 12 years.

Show evidence (1 reference)

PMID:33309813 SUPPORT Human Clinical

"All patients were symptomatic before 12 years of age (range, 0-11 years)."

Documents the distinctly early onset separating this subtype from typical progressive cone dystrophy.

Cone-rod dystrophy 6 (GUCY2D)

Dominant cone-rod dystrophy caused by GUCY2D dimerization-domain substitutions at R838. The mechanism is gain of function rather than loss, so simple gene supplementation would not be expected to correct it; editing approaches are under investigation but are not evidenced in this entry.

Show evidence (1 reference)

PMID:10430891 SUPPORT In Vitro

"increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca"

Establishes the dominant gain-of-function biochemistry defining this subtype.

⚙

Pathophysiology

8

Sustained Guanylate Cyclase Activation

In dominant disease, GCAP1 (GUCA1A) mutations in the EF-hand calcium-binding motifs lower calcium affinity so that GCAP1 fails to switch off retinal guanylate cyclase at the high calcium concentrations of the dark-adapted photoreceptor. GUCY2D dimerization-domain alleles act equivalently by raising the calcium set-point at which the cyclase remains GCAP1-stimulated. Both leave the cyclase inappropriately active.

retinal cone cell CL:0000573

phototransduction GO:0007602 ↕ DYSREGULATED

retina UBERON:0000966

Downstream

Cone Outer Segment cGMP Elevation An unrestrained cyclase overproduces cGMP in the cone outer segment.

Show evidence (2 references)

PMID:15790869 SUPPORT In Vitro

"GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely inhibited at high physiological"

Shows the mutant GCAP1 fails to inhibit the cyclase at physiological calcium, the defining biochemical lesion.

PMID:10430891 SUPPORT In Vitro

"increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca"

Shows the dominant GUCY2D allele alters the calcium sensitivity of cyclase regulation in the same direction.

Cone Phosphodiesterase Hydrolysis Failure

The recessive arm that reaches the cGMP node. PDE6C encodes the cone cGMP phosphodiesterase that degrades cGMP; biallelic loss removes the hydrolytic limb of the cycle and raises cGMP, arriving at the same lesion as an overactive cyclase.

retinal cone cell CL:0000573

cGMP metabolic process GO:0046068 ⚠ ABNORMAL

Downstream

Cone Outer Segment cGMP Elevation Loss of the hydrolysing phosphodiesterase raises cGMP just as an overactive cyclase does.

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"ffERG showed severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses and near-extinguished 30 Hz flicker responses, with relatively preserved rod-mediated scotopic responses."

Documents the cone-selective dysfunction that follows loss of the cone phosphodiesterase.

Cone CNG Channel Loss of Function

A distinct recessive arm that does not raise cGMP. CNGA3 and CNGB3 encode the cone cyclic nucleotide-gated channel, which reads the cGMP signal rather than degrading it. Biallelic loss removes the dark current, leaving cones chronically hyperpolarised with low rather than elevated outer-segment calcium, and abolishing cone signalling. Because the channel is the route by which cGMP elevation becomes calcium influx, its loss is also partially protective against the calcium-driven death pathway - which is why this arm is modelled separately from the cGMP node rather than feeding it.

retinal cone cell CL:0000573

phototransduction GO:0007602 ↓ DECREASED

Animal models

CNGB3-mutant dog Dog (Canis lupus familiaris) recapitulates Naturally occurring biallelic CNGB3 loss reproduces the cone channel defect, and restoring the gene restores cone function and day vision.

Downstream

Cone Photoreceptor Degeneration Loss of the dark current abolishes cone signalling, by a route independent of calcium overload. The cited evidence supports loss of cone function; progression to structural cone loss in this arm is not separately evidenced here.

Show evidence (1 reference)

PMID:35327647 SUPPORT Model Organism

"rd1*Cngb1-/- double-mutant mice, which lack the beta subunit of the rod cyclic nucleotide-gated (CNG) channel and are partially protected from rd1 degeneration"

Shows that removing the CNG channel is protective rather than degenerative via the calcium route, establishing that channel loss is not upstream of cGMP elevation.

Cone Outer Segment cGMP Elevation

The convergent biochemical lesion. Elevated cGMP in the cone outer segment holds cyclic nucleotide-gated channels open, admitting sodium and calcium and producing calcium overload. This node is genotype-agnostic, which is why it is an attractive neuroprotective target across otherwise unrelated genotypes.

retinal cone cell CL:0000573

calcium ion transport GO:0006816 ↑ INCREASED

fovea centralis UBERON:0001786

Downstream

Calpain and PARP Activation Calcium admitted through the cGMP-gated channel drives the calpain and PARP execution cascade.

Show evidence (3 references)

PMID:15790869 SUPPORT In Vitro

"GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely inhibited at high physiological"

Failure to inhibit the cyclase at physiological calcium is what sustains cGMP elevation at this node.

PMID:35327647 SUPPORT In Vitro

"The IRD pathology is often based on an accumulation of cGMP in photoreceptors"

Independently establishes cGMP accumulation in photoreceptors as the shared lesion of inherited retinal degeneration.

PMID:35327647 SUPPORT In Vitro

"high cGMP observed in degenerating rd1 rod photoreceptors activates the CNG channel in the outer segment, leading to Ca2+- influx and depolarization"

Evidences the calcium half of this node - cGMP holds the channel open and calcium enters.

RPGR Glutamylation Failure

The X-linked arm operates through a post-translational modification defect rather than the cGMP node. TTLL5 glutamylates RPGR-ORF15 in its glutamate- and glycine-rich repeat region, and loss of that modification causes photoreceptor degeneration with early mislocalisation of cone opsins. Distal truncating ORF15 variants that impair glutamylation associate with a cone-dominated phenotype.

retinal cone cell CL:0000573

photoreceptor cell maintenance GO:0045494 ⚠ ABNORMAL

Animal models

Ttll5 mutant mouse Mouse (Mus musculus) recapitulates Reproduces the loss of RPGR glutamylation and reads out photoreceptor degeneration with cone opsin mislocalisation.

Downstream

Cone Photoreceptor Degeneration Failed glutamylation leads to opsin mislocalisation and slow photoreceptor loss.

Show evidence (1 reference)

PMID:27162334 SUPPORT Model Organism

"Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization of cone opsins"

Establishes loss of RPGR glutamylation as the pathogenic mechanism, with cone opsin mislocalisation as the early cellular lesion.

Calpain and PARP Activation

The execution cascade. Calcium entering through cGMP-gated channels drives excessive activation of calpain and poly(ADP-ribose) polymerase, which together carry out photoreceptor cell death. The dependency runs through the channel: removing the CNG channel is partially protective, and PARP inhibition reduces calpain activity while the converse does not hold. This node is genotype-agnostic, which is why calpain and PARP inhibitors are the leading neuroprotective candidates across otherwise unrelated cone dystrophy genotypes.

retinal cone cell CL:0000573

programmed cell death GO:0012501 ↑ INCREASED protein poly-ADP-ribosylation GO:0070212 ↑ INCREASED

Downstream

Cone Photoreceptor Degeneration Calpain and PARP activity carries out photoreceptor cell death.

Show evidence (1 reference)

PMID:35327647 SUPPORT In Vitro

"Inhibitors of calpain or PARP have shown promise in preventing photoreceptor cell death"

Establishes calpain and PARP as the execution enzymes and as tractable neuroprotective targets.

Cone Photoreceptor Degeneration

Convergent cellular outcome. Cones of the fovea and macula are lost first, producing the central-vision phenotype; when the process extends to rods the disorder becomes cone-rod dystrophy. Structural loss is measurable as contraction of the subfoveal ellipsoid zone on optical coherence tomography.

retinal cone cell CL:0000573 retinal rod cell CL:0000604

macula lutea UBERON:0000053

Downstream

Progressive Central Vision Loss Loss of foveal and macular cones degrades central acuity and colour vision.

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses"

Documents the cone-selective functional loss that degeneration produces.

Progressive Central Vision Loss

Clinical endpoint. Central sensitivity declines faster in cone-rod dystrophy than in rod-cone disease, and the course is lifelong, progressive and legally blinding without being directly life-limiting.

macula lutea UBERON:0000053

Show evidence (1 reference)

PMID:41237986 SUPPORT Human Clinical

"CORD patients exhibited significantly faster rates of central retinal sensitivity decline. The annual MS16 decline rate was 10.8% (95% CI: 6.6, 14.8) in CORD vs 5.1% (95% CI: 2.9, 7.1) in rod-cone patients (P = .02)."

Quantifies the faster central sensitivity decline in the cone-rod phenotype relative to rod-cone disease.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Eye 6

Abnormal Electroretinogram HP:0000512

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"ffERG showed severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses and near-extinguished 30 Hz flicker responses, with relatively preserved rod-mediated scotopic responses."

States the photopic-selective ERG pattern with preserved scotopic responses.

Reduced Visual Acuity OBLIGATE HP:0007663

Show evidence (1 reference)

PMID:40736814 SUPPORT Human Clinical

"Patients usually present with decreased central vision and a color vision deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia) and light intolerance (photophobia)."

Establishes this feature among the presenting manifestations of progressive cone dystrophy.

Color Vision Defect VERY_FREQUENT HP:0000551

Show evidence (2 references)

PMID:33309813 SUPPORT Human Clinical

"Decreased visual acuity was present in all patients, and 4 other symptoms were common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus (38.6%)."

Gives colour vision loss at 78.6% in the 117-patient KCNV2/CDSRR cohort - an early-onset single-gene subtype, not the whole entity.

PMID:40736814 SUPPORT Human Clinical

"Patients usually present with decreased central vision and a color vision deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia) and light intolerance (photophobia)."

Establishes this feature among the presenting manifestations of progressive cone dystrophy.

Photophobia FREQUENT HP:0000613

Show evidence (2 references)

PMID:33309813 SUPPORT Human Clinical

"Decreased visual acuity was present in all patients, and 4 other symptoms were common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus (38.6%)."

Gives photophobia at 53.5% in the 117-patient KCNV2/CDSRR cohort - an early-onset single-gene subtype, not the whole entity.

PMID:40736814 SUPPORT Human Clinical

"Patients usually present with decreased central vision and a color vision deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia) and light intolerance (photophobia)."

Establishes this feature among the presenting manifestations of progressive cone dystrophy.

Nystagmus HP:0000639

Show evidence (1 reference)

PMID:33309813 SUPPORT Human Clinical

"Decreased visual acuity was present in all patients, and 4 other symptoms were common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus (38.6%)."

Gives the frequency of nystagmus in a 117-patient KCNV2 cone dystrophy cohort, supporting both the association and the band.

Nyctalopia FREQUENT HP:0000662

Show evidence (2 references)

PMID:33309813 SUPPORT Human Clinical

"Decreased visual acuity was present in all patients, and 4 other symptoms were common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus (38.6%)."

Gives nyctalopia at 43.6% in the 117-patient KCNV2/CDSRR cohort - an early-onset single-gene subtype, not the whole entity.

PMID:40736814 SUPPORT Human Clinical

"Over time, affected individuals develop night blindness and loss of peripheral field."

Documents secondary rod involvement emerging over the disease course.

Other 1

Cone Dystrophy Cone/cone-rod dystrophy HP:0000548

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses"

Documents the cone-selective dysfunction that defines the phenotype.

🧬

Genetic Associations

7

GUCA1A (Gain of Function)

Gene: GUCA1A hgnc:4678 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:15790869 SUPPORT In Vitro

"GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely inhibited at high physiological"

Demonstrates the gain-of-function biochemistry of a dominant GUCA1A allele.

GUCY2D (Gain of Function)

Gene: GUCY2D hgnc:4689 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:10430891 SUPPORT In Vitro

"increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca"

Establishes the dominant gain-of-function mechanism at the dimerization domain.

PDE6C (Loss of Function)

Gene: PDE6C hgnc:8787 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses"

Documents progressive cone dystrophy in PDE6C-associated disease.

RPGR (Loss of Function)

Gene: RPGR hgnc:10295 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:27162334 SUPPORT Model Organism

"Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization of cone opsins"

Establishes the RPGR glutamylation mechanism through its modifying enzyme.

TTLL5 (Loss of Function)

Gene: TTLL5 hgnc:19963 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:27162334 SUPPORT Model Organism

"Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization of cone opsins"

Demonstrates that loss of the glutamylase reproduces the RPGR retinal phenotype.

CNGA3 (Loss of Function)

Gene: CNGA3 hgnc:2150 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:42542214 SUPPORT Human Clinical

"Pooled analysis showed modest, but statistically significant, improvement in best-corrected visual acuity, with a mean difference of 2.65 ETDRS letters"

Establishes CNGA3 as a gene-therapy-addressable cone channel genotype with measured human outcomes.

CNGB3 (Loss of Function)

Gene: CNGB3 hgnc:2153 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:20378608 SUPPORT Model Organism

"restoration of cone function and day vision in two canine models of CNGB3 achromatopsia"

Documents CNGB3 as the genotype in which cone-directed gene supplementation was first shown to work.

💊

Medical Actions

2

Supportive Low-Vision Management

Action: supportive care Ontology label: Supportive Care NCIT:C15747

No approved cure exists. Management is supportive: tinted and edge-filter lenses for photophobia, refractive correction, low-vision aids, and genetic counselling.

Mechanism Target:

MODULATES Progressive Central Vision Loss — Optical and low-vision measures mitigate the functional consequences of central cone loss without altering the degeneration itself.

Show evidence (1 reference)

PMID:40736814 SUPPORT Human Clinical

"Patients usually present with decreased central vision and a color vision deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia) and light intolerance (photophobia)."

Names the symptom burden - photophobia, day blindness and central acuity loss - that optical and low-vision measures address.

Show evidence (1 reference)

PMID:40736814 SUPPORT Human Clinical

"Visual acuity deteriorates to 20/200 or even counting fingers."

The degree of acuity loss that makes low-vision rehabilitation the mainstay of management.

AAV Gene Supplementation

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Experimental, and the most advanced therapeutic frontier. Subretinal AAV delivery of the wild-type gene restored cone function and day vision in canine CNGB3 achromatopsia, providing the proof of concept for recessive loss-of-function cone disease. Dominant gain-of-function GUCY2D disease is not addressable by supplementation alone and requires editing approaches.

Mechanism Target:

RESTORES Cone CNG Channel Loss of Function — Supplying a functional copy of CNGA3 or CNGB3 restores the cone dark current and with it cone phototransduction. This is the arm the approved-trial gene therapies address; the cGMP-elevating arms are not corrected by supplementation.

Show evidence (1 reference)

PMID:20378608 SUPPORT Model Organism

"restoration of cone function and day vision in two canine models of CNGB3 achromatopsia"

Demonstrates restoration of the failed cone pathway by gene supplementation.

Show evidence (2 references)

PMID:20378608 SUPPORT Model Organism

"rAAV-mediated gene replacement therapy with different forms of the human red cone opsin promoter led to the restoration of cone function and day vision in two canine models of CNGB3 achromatopsia"

Documents the AAV construct and the functional rescue achieved in the preclinical model.

PMID:42542214 SUPPORT Human Clinical

"Pooled analysis showed modest, but statistically significant, improvement in best-corrected visual acuity, with a mean difference of 2.65 ETDRS letters, and significant improvement in contrast sensitivity."

Pools nine human trials; the benefit is real but modest, which is why this is recorded as PARTIAL rather than full support for clinical efficacy.

🔬

Diagnosis

2

Electroretinography

Full-field electroretinography is the decisive test. Cone dystrophy shows a photopic-selective deficit with markedly reduced light-adapted single-flash and near-extinguished 30 Hz flicker responses, while scotopic rod responses remain relatively preserved.

electroretinography NCIT:C156778

Show evidence (1 reference)

PMID:42525358 SUPPORT Human Clinical

"ffERG showed severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses and near-extinguished 30 Hz flicker responses, with relatively preserved rod-mediated scotopic responses."

States the photopic-selective electroretinographic pattern that establishes the diagnosis.

Molecular genetic testing

Gene-panel or exome sequencing establishes the molecular diagnosis and is required for eligibility for genotype-directed therapy. Diagnostic yield is comparatively low in this phenotype, reflecting extensive genetic heterogeneity and variants such as those in the repetitive RPGR-ORF15 region that are hard to detect with short-read sequencing.

genetic testing NCIT:C15709

Show evidence (1 reference)

PMID:40571344 SUPPORT Human Clinical

"The lowest rates of causative variant identification were observed in cone or cone-rod dystrophy and macular dystrophy."

Documents the comparatively low molecular diagnostic yield in this phenotype.

📈

Progression

2

Onset and diagnosis

Age: Mid-teenage years or later in most progressive forms; before 12 years in KCNV2 disease

Presentation is usually with declining central acuity, colour vision loss and photophobia. Diagnosis follows the photopic-selective electroretinogram. Early-onset forms such as KCNV2 disease present considerably sooner.

Show evidence (2 references)

PMID:40736814 SUPPORT Human Clinical

"A heterogenous group of diseases, progressive cone dystrophy usually begins in the mid-teenage years or later in life."

States the onset window for typical progressive disease.

PMID:33309813 SUPPORT Human Clinical

"All patients were symptomatic before 12 years of age (range, 0-11 years)."

Documents the much earlier onset of the KCNV2 subtype, which the age range brackets.

Progressive central sensitivity loss

Central retinal sensitivity declines faster in the cone-rod phenotype than in rod-cone disease, giving a shorter interval to total central sensitivity loss. The disease is lifelong and legally blinding but not directly life-limiting.

Show evidence (1 reference)

PMID:41237986 SUPPORT Human Clinical

"The median survival age to total loss of sensitivity for MS16 was 25.1 years in CORD and 33.1 years in rod-cone"

Gives the interval to total central sensitivity loss, the long-term functional endpoint.

📊

Prevalence

1

Israel, nationwide inherited retinal disease cohort

Point Prevalence 1–9 per 100,000

Cone-rod dystrophy was the second most common inherited retinal disease at approximately 1 in 14,000, after retinitis pigmentosa.

Show evidence (1 reference)

PMID:38753338 SUPPORT Human Clinical

"the most common IRD in Israel was retinitis pigmentosa with a disease prevalence of approximately 1:2400 individuals, followed by cone-rod dystrophy (approximately 1:14 000)"

Provides the population prevalence of cone-rod dystrophy and its rank among inherited retinal diseases.

🐁

Animal Models

2

Ttll5 mutant mouse Knockout

Loss of the RPGR glutamylase in mouse produces slow photoreceptor degeneration with early cone opsin mislocalisation, resembling Rpgr-null mice and establishing glutamylation as the pathogenic variable.

Species

Mouse (Mus musculus)

Genotype

Ttll5 mutant

Genes

TTLL5 hgnc:19963

Pathograph links

RPGR Glutamylation Failure recapitulates fidelity: high Reproduces the loss of RPGR glutamylation and reads out photoreceptor degeneration with cone opsin mislocalisation.

Limitations: Models the glutamylation defect via the modifying enzyme rather than via the RPGR ORF15 repeat variants that cause most human X-linked disease.

Show evidence (1 reference)

PMID:27162334 SUPPORT Model Organism

"Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization of cone opsins"

The readout grounding this model link.

Show evidence (1 reference)

PMID:27162334 SUPPORT Model Organism

"Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization of cone opsins"

Establishes the mouse phenotype and its resemblance to Rpgr-null animals.

CNGB3-mutant dog Spontaneous

Naturally occurring canine CNGB3 achromatopsia was the model in which AAV gene supplementation restored cone function and day vision, establishing proof of concept for cone-directed gene therapy.

Species

Dog (Canis lupus familiaris)

Genotype

CNGB3-mutant achromatopsia

Genes

CNGB3 hgnc:2153

Pathograph links

Cone CNG Channel Loss of Function recapitulates fidelity: high Naturally occurring biallelic CNGB3 loss reproduces the cone channel defect, and restoring the gene restores cone function and day vision.

Limitations: Canine cone topography differs from the human fovea, so the readout is day vision rather than central acuity.

Show evidence (1 reference)

PMID:20378608 SUPPORT Model Organism

"restoration of cone function and day vision in two canine models of CNGB3 achromatopsia"

The rescue readout that grounds this model link.

Show evidence (1 reference)

PMID:20378608 SUPPORT Model Organism

"restoration of cone function and day vision in two canine models of CNGB3 achromatopsia"

Documents functional rescue in the canine model.

{ }

Source YAML

click to show

name: Cone Dystrophy
creation_date: '2026-08-27T21:30:00Z'
synonyms:
- cone-rod dystrophy
- progressive cone dystrophy
- COD
- CORD
description: >-
  Cone dystrophy is a genetically heterogeneous inherited retinal dystrophy
  defined by primary dysfunction and progressive degeneration of the cone
  photoreceptors that populate the fovea and macula. Patients present with
  declining central visual acuity, colour vision loss, photophobia and, in
  early-onset forms, nystagmus. When rod photoreceptors become secondarily
  involved the disorder is termed cone-rod dystrophy, which adds night blindness
  and peripheral field loss. It is among the more common inherited retinal
  diseases after retinitis pigmentosa, with cone-rod dystrophy prevalence around
  1 in 14,000 in a nationwide cohort. Mechanistically a large fraction of cases
  converge on dysregulation of the cGMP/calcium phototransduction node in cone
  outer segments: dominant gain-of-function alleles of GUCA1A and GUCY2D cause
  aberrantly sustained cGMP synthesis, while recessive loss of PDE6C, the cone cGMP
  phosphodiesterase, removes the hydrolytic limb of the same cycle. Recessive loss
  of the CNGA3/CNGB3 cone channel is a separate arm: the channel reads the cGMP
  signal rather than degrading it, so its loss abolishes the dark current instead
  of raising cGMP.
  Other forms act through ciliary trafficking and post-translational modification
  defects (RPGR, TTLL5), visual-cycle dysfunction (ABCA4), or transcriptional
  dysregulation (CRX). Diagnosis rests on a photopic-selective electroretinogram
  deficit with relatively preserved scotopic responses, combined with optical
  coherence tomography and gene-panel sequencing. No approved cure exists;
  management is supportive, and AAV gene supplementation is the most advanced
  experimental therapy.
categories:
- Inherited Retinal Dystrophy
- Photoreceptor Degeneration
- Mendelian
parents:
- retinal dystrophy
has_subtypes:
- name: CDSRR
  display_name: Cone dystrophy with supernormal rod response (KCNV2)
  description: >-
    KCNV2-associated retinopathy, distinguished by a pathognomonic delayed
    supernormal rod b-wave with a squared a-wave on the dark-adapted
    electroretinogram. Onset is much earlier than typical progressive cone
    dystrophy, with all patients symptomatic before 12 years.
  evidence:
  - reference: PMID:33309813
    reference_title: 'KCNV2-Associated Retinopathy: Genetics, Electrophysiology, and Clinical
      Course-KCNV2 Study Group Report 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients were symptomatic before 12 years of age (range, 0-11 years).
    explanation: Documents the distinctly early onset separating this subtype from typical
      progressive cone dystrophy.
- name: CORD6
  display_name: Cone-rod dystrophy 6 (GUCY2D)
  description: >-
    Dominant cone-rod dystrophy caused by GUCY2D dimerization-domain
    substitutions at R838. The mechanism is gain of function rather than loss, so
    simple gene supplementation would not be expected to correct it; editing
    approaches are under investigation but are not evidenced in this entry.
  evidence:
  - reference: PMID:10430891
    reference_title: Biochemical analysis of a dimerization domain mutation in RetGC-1 associated
      with dominant cone-rod dystrophy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca
    explanation: Establishes the dominant gain-of-function biochemistry defining this subtype.
prevalence:
- population: Israel, nationwide inherited retinal disease cohort
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  notes: >-
    Cone-rod dystrophy was the second most common inherited retinal disease at
    approximately 1 in 14,000, after retinitis pigmentosa.
  evidence:
  - reference: PMID:38753338
    reference_title: Nationwide Prevalence of Inherited Retinal Diseases in the Israeli
      Population.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the most common IRD in Israel was retinitis pigmentosa with a disease prevalence
      of approximately 1:2400 individuals, followed by cone-rod dystrophy (approximately
      1:14 000)
    explanation: Provides the population prevalence of cone-rod dystrophy and its rank among
      inherited retinal diseases.
inheritance:
- name: Autosomal Dominant
  description: >-
    Dominant disease is typically caused by gain-of-function alleles of GUCA1A or
    GUCY2D that leave retinal guanylate cyclase inappropriately active.
  inheritance_term:
    preferred_term: autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:15790869
    reference_title: A novel GCAP1 missense mutation (L151F) in a large family with autosomal
      dominant cone-rod dystrophy (adCORD).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Affected family members harbored a C-->T transition in exon 4 of the GCAP1 gene,
      resulting in an L151F missense mutation affecting the
    explanation: Documents segregation of the GCAP1 allele with affected status in a
      pedigree studied for autosomal dominant cone-rod dystrophy.
- name: Autosomal Recessive
  description: >-
    Recessive disease arises from biallelic loss of function in the cone
    phototransduction machinery, including PDE6C and the CNGA3/CNGB3 channel
    subunits.
  inheritance_term:
    preferred_term: autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Genetic testing identified two heterozygous PDE6C variants: a likely pathogenic
      frameshift variant (c.2304_2305delAA; p.Asp770Ter), predicted to result in premature truncation
      of the protein, and a'
    explanation: Documents biallelic PDE6C variants in an affected individual, the transmission
      pattern this inheritance mode asserts.
- name: X-Linked
  description: >-
    X-linked cone and cone-rod dystrophy is caused by RPGR variants, particularly
    distal truncating variants in the ORF15 repeat region that impair
    glutamylation of the RPGR protein.
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  evidence:
  - reference: PMID:41481301
    reference_title: Phenotypic Manifestations in Female Carriers of RPGR ORF15 Variants Causing
      X-Linked Cone Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recent insights into impaired glutamylation caused by distal truncating variants in RPGR
      ORF15 and its association with the cone-dominated phenotype have provided the first
      molecular evidence of a genotype-phenotype correlation in male individuals with X-linked
      RPGR-related retinal dystrophy
    explanation: Establishes the X-linked RPGR ORF15 genotype-phenotype correlation in
      hemizygous males - the correct gene, species and mode of inheritance.
pathophysiology:
- name: Sustained Guanylate Cyclase Activation
  description: >-
    In dominant disease, GCAP1 (GUCA1A) mutations in the EF-hand calcium-binding
    motifs lower calcium affinity so that GCAP1 fails to switch off retinal
    guanylate cyclase at the high calcium concentrations of the dark-adapted
    photoreceptor. GUCY2D dimerization-domain alleles act equivalently by raising
    the calcium set-point at which the cyclase remains GCAP1-stimulated. Both
    leave the cyclase inappropriately active.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: phototransduction
    modifier: DYSREGULATED
    term:
      id: GO:0007602
      label: phototransduction
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  evidence:
  - reference: PMID:15790869
    reference_title: A novel GCAP1 missense mutation (L151F) in a large family with autosomal
      dominant cone-rod dystrophy (adCORD).
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely
      inhibited at high physiological
    explanation: Shows the mutant GCAP1 fails to inhibit the cyclase at physiological calcium,
      the defining biochemical lesion.
  - reference: PMID:10430891
    reference_title: Biochemical analysis of a dimerization domain mutation in RetGC-1 associated
      with dominant cone-rod dystrophy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca
    explanation: Shows the dominant GUCY2D allele alters the calcium sensitivity of cyclase
      regulation in the same direction.
  downstream:
  - target: Cone Outer Segment cGMP Elevation
    description: An unrestrained cyclase overproduces cGMP in the cone outer segment.
    evidence:
    - reference: PMID:10430891
      reference_title: Biochemical analysis of a dimerization domain mutation in RetGC-1
        associated with dominant cone-rod dystrophy.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca
      explanation: Persistent GCAP-1 stimulation of the cyclase is what raises cGMP.
- name: Cone Phosphodiesterase Hydrolysis Failure
  description: >-
    The recessive arm that reaches the cGMP node. PDE6C encodes the cone cGMP
    phosphodiesterase that degrades cGMP; biallelic loss removes the hydrolytic
    limb of the cycle and raises cGMP, arriving at the same lesion as an
    overactive cyclase.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: cGMP metabolic process
    modifier: ABNORMAL
    term:
      id: GO:0046068
      label: cGMP metabolic process
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ffERG showed severe cone dysfunction, characterized by markedly reduced light-adapted
      single-flash responses and near-extinguished 30 Hz flicker responses, with relatively
      preserved rod-mediated scotopic responses.
    explanation: Documents the cone-selective dysfunction that follows loss of the cone
      phosphodiesterase.
  downstream:
  - target: Cone Outer Segment cGMP Elevation
    description: Loss of the hydrolysing phosphodiesterase raises cGMP just as an overactive
      cyclase does.
    evidence:
    - reference: PMID:35327647
      reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
        Requires CNG Channel Activity.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The IRD pathology is often based on an accumulation of cGMP in photoreceptors
      explanation: Establishes cGMP accumulation as the shared lesion that phosphodiesterase
        loss produces.
- name: Cone CNG Channel Loss of Function
  description: >-
    A distinct recessive arm that does not raise cGMP. CNGA3 and CNGB3 encode the
    cone cyclic nucleotide-gated channel, which reads the cGMP signal rather than
    degrading it. Biallelic loss removes the dark current, leaving cones
    chronically hyperpolarised with low rather than elevated outer-segment
    calcium, and abolishing cone signalling. Because the channel is the route by
    which cGMP elevation becomes calcium influx, its loss is also partially
    protective against the calcium-driven death pathway - which is why this arm is
    modelled separately from the cGMP node rather than feeding it.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: phototransduction
    modifier: DECREASED
    term:
      id: GO:0007602
      label: phototransduction
  evidence:
  - reference: PMID:35327647
    reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
      Requires CNG Channel Activity.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: rd1*Cngb1-/- double-mutant mice, which lack the beta subunit of the rod cyclic
      nucleotide-gated (CNG) channel and are partially protected from rd1 degeneration
    explanation: Shows that removing the CNG channel is protective rather than degenerative
      via the calcium route, establishing that channel loss is not upstream of cGMP elevation.
  downstream:
  - target: Cone Photoreceptor Degeneration
    description: Loss of the dark current abolishes cone signalling, by a route independent
      of calcium overload. The cited evidence supports loss of cone function; progression to
      structural cone loss in this arm is not separately evidenced here.
    evidence:
    - reference: PMID:20378608
      reference_title: Gene therapy rescues cone function in congenital achromatopsia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: restoration of cone function and day vision in two canine models of CNGB3 achromatopsia
      explanation: Restoring the channel restores cone function, showing channel loss is what
        abolishes it.
- name: Cone Outer Segment cGMP Elevation
  description: >-
    The convergent biochemical lesion. Elevated cGMP in the cone outer segment
    holds cyclic nucleotide-gated channels open, admitting sodium and calcium and
    producing calcium overload. This node is genotype-agnostic, which is why it is
    an attractive neuroprotective target across otherwise unrelated genotypes.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: calcium ion transport
    modifier: INCREASED
    term:
      id: GO:0006816
      label: calcium ion transport
  locations:
  - preferred_term: fovea centralis
    term:
      id: UBERON:0001786
      label: fovea centralis
  evidence:
  - reference: PMID:15790869
    reference_title: A novel GCAP1 missense mutation (L151F) in a large family with autosomal
      dominant cone-rod dystrophy (adCORD).
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely
      inhibited at high physiological
    explanation: Failure to inhibit the cyclase at physiological calcium is what sustains
      cGMP elevation at this node.
  - reference: PMID:35327647
    reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
      Requires CNG Channel Activity.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The IRD pathology is often based on an accumulation of cGMP in photoreceptors
    explanation: Independently establishes cGMP accumulation in photoreceptors as the shared
      lesion of inherited retinal degeneration.
  - reference: PMID:35327647
    reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
      Requires CNG Channel Activity.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: high cGMP observed in degenerating rd1 rod photoreceptors activates the CNG channel
      in the outer segment, leading to Ca2+- influx and depolarization
    explanation: Evidences the calcium half of this node - cGMP holds the channel open and
      calcium enters.
  downstream:
  - target: Calpain and PARP Activation
    description: Calcium admitted through the cGMP-gated channel drives the calpain and PARP
      execution cascade.
    evidence:
    - reference: PMID:35327647
      reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
        Requires CNG Channel Activity.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The IRD pathology is often based on an accumulation of cGMP in photoreceptors
        and associated with the excessive activation of calpain and poly (ADP-ribose) polymerase
        (PARP).
      explanation: Links cGMP accumulation to excessive calpain and PARP activation, and the
        paper's title establishes that this requires CNG channel activity.
- name: RPGR Glutamylation Failure
  description: >-
    The X-linked arm operates through a post-translational modification defect
    rather than the cGMP node. TTLL5 glutamylates RPGR-ORF15 in its glutamate-
    and glycine-rich repeat region, and loss of that modification causes
    photoreceptor degeneration with early mislocalisation of cone opsins. Distal
    truncating ORF15 variants that impair glutamylation associate with a
    cone-dominated phenotype.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: photoreceptor cell maintenance
    modifier: ABNORMAL
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
  evidence:
  - reference: PMID:27162334
    reference_title: Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal
      dystrophy caused by TTLL5 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization
      of cone opsins
    explanation: Establishes loss of RPGR glutamylation as the pathogenic mechanism, with
      cone opsin mislocalisation as the early cellular lesion.
  downstream:
  - target: Cone Photoreceptor Degeneration
    description: Failed glutamylation leads to opsin mislocalisation and slow photoreceptor
      loss.
    evidence:
    - reference: PMID:27162334
      reference_title: Loss of RPGR glutamylation underlies the pathogenic mechanism of
        retinal dystrophy caused by TTLL5 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization
        of cone opsins
      explanation: Directly links the glutamylation defect to progressive photoreceptor
        degeneration.
- name: Calpain and PARP Activation
  description: >-
    The execution cascade. Calcium entering through cGMP-gated channels drives
    excessive activation of calpain and poly(ADP-ribose) polymerase, which
    together carry out photoreceptor cell death. The dependency runs through the
    channel: removing the CNG channel is partially protective, and PARP inhibition
    reduces calpain activity while the converse does not hold. This node is
    genotype-agnostic, which is why calpain and PARP inhibitors are the leading
    neuroprotective candidates across otherwise unrelated cone dystrophy genotypes.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: programmed cell death
    modifier: INCREASED
    term:
      id: GO:0012501
      label: programmed cell death
  - preferred_term: protein poly-ADP-ribosylation
    modifier: INCREASED
    term:
      id: GO:0070212
      label: protein poly-ADP-ribosylation
  evidence:
  - reference: PMID:35327647
    reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
      Requires CNG Channel Activity.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Inhibitors of calpain or PARP have shown promise in preventing photoreceptor cell
      death
    explanation: Establishes calpain and PARP as the execution enzymes and as tractable
      neuroprotective targets.
  downstream:
  - target: Cone Photoreceptor Degeneration
    description: Calpain and PARP activity carries out photoreceptor cell death.
    evidence:
    - reference: PMID:35327647
      reference_title: 'Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain
        Requires CNG Channel Activity.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We confirmed that an inhibition of either calpain or PARP reduces photoreceptor
        cell death in rd1 retina.
      explanation: Blocking either enzyme reduces photoreceptor death, establishing the causal
        direction of this edge.
- name: Cone Photoreceptor Degeneration
  description: >-
    Convergent cellular outcome. Cones of the fovea and macula are lost first,
    producing the central-vision phenotype; when the process extends to rods the
    disorder becomes cone-rod dystrophy. Structural loss is measurable as
    contraction of the subfoveal ellipsoid zone on optical coherence tomography.
  cell_types:
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  locations:
  - preferred_term: macula lutea
    term:
      id: UBERON:0000053
      label: macula lutea
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: severe cone dysfunction, characterized by markedly reduced light-adapted single-flash
      responses
    explanation: Documents the cone-selective functional loss that degeneration produces.
  downstream:
  - target: Progressive Central Vision Loss
    description: Loss of foveal and macular cones degrades central acuity and colour vision.
    evidence:
    - reference: PMID:40736814
      reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Visual acuity deteriorates to 20/200 or even counting fingers.
      explanation: Quantifies the endpoint acuity reached as foveal cones are lost.
- name: Progressive Central Vision Loss
  description: >-
    Clinical endpoint. Central sensitivity declines faster in cone-rod dystrophy
    than in rod-cone disease, and the course is lifelong, progressive and
    legally blinding without being directly life-limiting.
  locations:
  - preferred_term: macula lutea
    term:
      id: UBERON:0000053
      label: macula lutea
  evidence:
  - reference: PMID:41237986
    reference_title: Central Retinal Sensitivity Decline in RPGR-Related Retinal Phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CORD patients exhibited significantly faster rates of central retinal sensitivity
      decline. The annual MS16 decline rate was 10.8% (95% CI: 6.6, 14.8) in CORD vs 5.1%
      (95% CI: 2.9, 7.1) in rod-cone patients (P = .02).
    explanation: Quantifies the faster central sensitivity decline in the cone-rod phenotype
      relative to rod-cone disease.
phenotypes:
- category: Ophthalmologic
  name: Cone Dystrophy
  description: >-
    The defining phenotype: primary cone photoreceptor dysfunction and
    progressive degeneration, with rod involvement in the cone-rod form.
  phenotype_term:
    preferred_term: Cone/cone-rod dystrophy
    term:
      id: HP:0000548
      label: Cone/cone-rod dystrophy
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: severe cone dysfunction, characterized by markedly reduced light-adapted single-flash
      responses
    explanation: Documents the cone-selective dysfunction that defines the phenotype.
- category: Ophthalmologic
  name: Abnormal Electroretinogram
  description: >-
    The diagnostic electrophysiological signature is a photopic-selective deficit:
    markedly reduced light-adapted single-flash and near-extinguished 30 Hz
    flicker responses, with relatively preserved scotopic rod responses.
  phenotype_term:
    preferred_term: Abnormal electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ffERG showed severe cone dysfunction, characterized by markedly reduced light-adapted
      single-flash responses and near-extinguished 30 Hz flicker responses, with relatively
      preserved rod-mediated scotopic responses.
    explanation: States the photopic-selective ERG pattern with preserved scotopic responses.
- category: Ophthalmologic
  name: Reduced Visual Acuity
  description: >-
    Declining central visual acuity is the usual presenting complaint, reflecting
    loss of the foveal cone population.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  frequency: OBLIGATE
  evidence:
  - reference: PMID:40736814
    reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients usually present with decreased central vision and a color vision deficit;
      the visual loss is progressive and often accompanied by day blindness (hemeralopia)
      and light intolerance (photophobia).
    explanation: Establishes this feature among the presenting manifestations of progressive
      cone dystrophy.
- category: Ophthalmologic
  name: Color Vision Defect
  description: >-
    Dyschromatopsia follows directly from cone loss and is often present early,
    before acuity decline becomes marked.
  phenotype_term:
    preferred_term: Color vision defect
    term:
      id: HP:0000551
      label: Color vision defect
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:33309813
    reference_title: 'KCNV2-Associated Retinopathy: Genetics, Electrophysiology, and Clinical
      Course-KCNV2 Study Group Report 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Decreased visual acuity was present in all patients, and 4 other symptoms were
      common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus
      (38.6%).'
    explanation: Gives colour vision loss at 78.6% in the 117-patient KCNV2/CDSRR cohort - an early-onset single-gene subtype, not the whole entity.
  - reference: PMID:40736814
    reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients usually present with decreased central vision and a color vision deficit;
      the visual loss is progressive and often accompanied by day blindness (hemeralopia)
      and light intolerance (photophobia).
    explanation: Establishes this feature among the presenting manifestations of progressive
      cone dystrophy.
- category: Ophthalmologic
  name: Photophobia
  description: >-
    Glare intolerance and day-blindness reflect the loss of the photopic system
    that would normally operate at high luminance.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  frequency: FREQUENT
  evidence:
  - reference: PMID:33309813
    reference_title: 'KCNV2-Associated Retinopathy: Genetics, Electrophysiology, and Clinical
      Course-KCNV2 Study Group Report 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Decreased visual acuity was present in all patients, and 4 other symptoms were
      common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus
      (38.6%).'
    explanation: Gives photophobia at 53.5% in the 117-patient KCNV2/CDSRR cohort - an early-onset single-gene subtype, not the whole entity.
  - reference: PMID:40736814
    reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients usually present with decreased central vision and a color vision deficit;
      the visual loss is progressive and often accompanied by day blindness (hemeralopia)
      and light intolerance (photophobia).
    explanation: Establishes this feature among the presenting manifestations of progressive
      cone dystrophy.
- category: Ophthalmologic
  name: Nystagmus
  description: >-
    Nystagmus occurs in early-onset forms, where poor foveal fixation develops
    before visual maturation is complete.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:33309813
    reference_title: 'KCNV2-Associated Retinopathy: Genetics, Electrophysiology, and Clinical
      Course-KCNV2 Study Group Report 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Decreased visual acuity was present in all patients, and 4 other symptoms were
      common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus
      (38.6%).'
    explanation: Gives the frequency of nystagmus in a 117-patient KCNV2 cone dystrophy cohort,
      supporting both the association and the band.
- category: Ophthalmologic
  name: Nyctalopia
  description: >-
    Night blindness marks secondary rod involvement and the transition from pure
    cone dystrophy to cone-rod dystrophy.
  phenotype_term:
    preferred_term: Nyctalopia
    term:
      id: HP:0000662
      label: Nyctalopia
  frequency: FREQUENT
  evidence:
  - reference: PMID:33309813
    reference_title: 'KCNV2-Associated Retinopathy: Genetics, Electrophysiology, and Clinical
      Course-KCNV2 Study Group Report 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Decreased visual acuity was present in all patients, and 4 other symptoms were
      common: reduced color vision (78.6%), photophobia (53.5%), nyctalopia (43.6%), and nystagmus
      (38.6%).'
    explanation: Gives nyctalopia at 43.6% in the 117-patient KCNV2/CDSRR cohort - an early-onset single-gene subtype, not the whole entity.
  - reference: PMID:40736814
    reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Over time, affected individuals develop night blindness and loss of peripheral
      field.
    explanation: Documents secondary rod involvement emerging over the disease course.
genetic:
- name: GUCA1A
  gene_term:
    preferred_term: GUCA1A
    term:
      id: hgnc:4678
      label: GUCA1A
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Gain of Function
  notes: >-
    Encodes GCAP1. Missense variants in the EF-hand calcium-binding motifs lower
    calcium affinity so the protein cannot switch off retinal guanylate cyclase in
    the dark-adapted photoreceptor, producing dominant cone-rod dystrophy.
  evidence:
  - reference: PMID:15790869
    reference_title: A novel GCAP1 missense mutation (L151F) in a large family with autosomal
      dominant cone-rod dystrophy (adCORD).
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely
      inhibited at high physiological
    explanation: Demonstrates the gain-of-function biochemistry of a dominant GUCA1A allele.
- name: GUCY2D
  gene_term:
    preferred_term: GUCY2D
    term:
      id: hgnc:4689
      label: GUCY2D
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Gain of Function
  notes: >-
    Encodes retinal guanylate cyclase RetGC-1. Dimerization-domain substitutions
    (R838C/R838S, CORD6) raise the calcium set-point at which the cyclase remains
    GCAP-1 stimulated, so cGMP synthesis continues inappropriately.
  evidence:
  - reference: PMID:10430891
    reference_title: Biochemical analysis of a dimerization domain mutation in RetGC-1 associated
      with dominant cone-rod dystrophy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca
    explanation: Establishes the dominant gain-of-function mechanism at the dimerization
      domain.
- name: PDE6C
  gene_term:
    preferred_term: PDE6C
    term:
      id: hgnc:8787
      label: PDE6C
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Loss of Function
  notes: >-
    Encodes the cone cGMP phosphodiesterase. Biallelic loss removes the hydrolytic
    arm of the cGMP cycle and produces progressive cone dystrophy on an
    achromatopsia background.
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: severe cone dysfunction, characterized by markedly reduced light-adapted single-flash
      responses
    explanation: Documents progressive cone dystrophy in PDE6C-associated disease.
- name: RPGR
  gene_term:
    preferred_term: RPGR
    term:
      id: hgnc:10295
      label: RPGR
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Loss of Function
  notes: >-
    The principal X-linked locus. Distal truncating variants in the ORF15 repeat
    region impair TTLL5-mediated glutamylation of the RPGR protein and associate
    with a cone-dominated rather than rod-dominated phenotype.
  evidence:
  - reference: PMID:27162334
    reference_title: Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal
      dystrophy caused by TTLL5 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization
      of cone opsins
    explanation: Establishes the RPGR glutamylation mechanism through its modifying enzyme.
- name: TTLL5
  gene_term:
    preferred_term: TTLL5
    term:
      id: hgnc:19963
      label: TTLL5
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Loss of Function
  notes: >-
    Encodes the glutamylase that modifies RPGR-ORF15. Loss phenocopies RPGR
    disease, which is the evidence that glutamylation rather than RPGR abundance
    is the critical variable. Note that TTLL5 is itself autosomal (14q24.3) and
    TTLL5-related dystrophy is recessive; it sits in this X-linked narrative
    because of its substrate, not because it shares the mode of inheritance.
  evidence:
  - reference: PMID:27162334
    reference_title: Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal
      dystrophy caused by TTLL5 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization
      of cone opsins
    explanation: Demonstrates that loss of the glutamylase reproduces the RPGR retinal
      phenotype.
- name: CNGA3
  gene_term:
    preferred_term: CNGA3
    term:
      id: hgnc:2150
      label: CNGA3
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Loss of Function
  notes: >-
    Encodes the alpha subunit of the cone cyclic nucleotide-gated channel.
    Biallelic loss removes the cone dark current. One of the two genotypes
    addressed by AAV gene supplementation trials.
  evidence:
  - reference: PMID:42542214
    reference_title: 'The efficacy and safety of adeno-associated virus-mediated gene therapy
      for CNGA3- and CNGB3-associated achromatopsia: A genotype-aware systematic review and
      meta-analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pooled analysis showed modest, but statistically significant, improvement in best-corrected
      visual acuity, with a mean difference of 2.65 ETDRS letters
    explanation: Establishes CNGA3 as a gene-therapy-addressable cone channel genotype with
      measured human outcomes.
- name: CNGB3
  gene_term:
    preferred_term: CNGB3
    term:
      id: hgnc:2153
      label: CNGB3
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  association: Loss of Function
  notes: >-
    Encodes the beta subunit of the cone cyclic nucleotide-gated channel and is
    the commonest cause of channel-related cone dysfunction. The canine CNGB3
    model provided the original proof of concept for cone-directed gene therapy.
  evidence:
  - reference: PMID:20378608
    reference_title: Gene therapy rescues cone function in congenital achromatopsia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: restoration of cone function and day vision in two canine models of CNGB3 achromatopsia
    explanation: Documents CNGB3 as the genotype in which cone-directed gene supplementation
      was first shown to work.
animal_models:
- name: Ttll5 mutant mouse
  species: Mouse (Mus musculus)
  genotype: Ttll5 mutant
  category: Knockout
  description: >-
    Loss of the RPGR glutamylase in mouse produces slow photoreceptor
    degeneration with early cone opsin mislocalisation, resembling Rpgr-null
    mice and establishing glutamylation as the pathogenic variable.
  genes:
  - preferred_term: TTLL5
    term:
      id: hgnc:19963
      label: TTLL5
  associated_phenotypes:
  - Photoreceptor degeneration
  - Cone opsin mislocalization
  modeled_mechanisms:
  - target: RPGR Glutamylation Failure
    relationship: RECAPITULATES
    description: >-
      Reproduces the loss of RPGR glutamylation and reads out photoreceptor
      degeneration with cone opsin mislocalisation.
    fidelity: HIGH
    limitations: >-
      Models the glutamylation defect via the modifying enzyme rather than via the
      RPGR ORF15 repeat variants that cause most human X-linked disease.
    evidence:
    - reference: PMID:27162334
      reference_title: Loss of RPGR glutamylation underlies the pathogenic mechanism of
        retinal dystrophy caused by TTLL5 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization
        of cone opsins
      explanation: The readout grounding this model link.
  evidence:
  - reference: PMID:27162334
    reference_title: Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal
      dystrophy caused by TTLL5 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization
      of cone opsins
    explanation: Establishes the mouse phenotype and its resemblance to Rpgr-null animals.
- name: CNGB3-mutant dog
  species: Dog (Canis lupus familiaris)
  genotype: CNGB3-mutant achromatopsia
  category: Spontaneous
  description: >-
    Naturally occurring canine CNGB3 achromatopsia was the model in which AAV
    gene supplementation restored cone function and day vision, establishing
    proof of concept for cone-directed gene therapy.
  genes:
  - preferred_term: CNGB3
    term:
      id: hgnc:2153
      label: CNGB3
  associated_phenotypes:
  - Cone dysfunction
  - Day blindness
  modeled_mechanisms:
  - target: Cone CNG Channel Loss of Function
    relationship: RECAPITULATES
    description: >-
      Naturally occurring biallelic CNGB3 loss reproduces the cone channel defect, and
      restoring the gene restores cone function and day vision.
    fidelity: HIGH
    limitations: >-
      Canine cone topography differs from the human fovea, so the readout is day vision
      rather than central acuity.
    evidence:
    - reference: PMID:20378608
      reference_title: Gene therapy rescues cone function in congenital achromatopsia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: restoration of cone function and day vision in two canine models of CNGB3 achromatopsia
      explanation: The rescue readout that grounds this model link.
  evidence:
  - reference: PMID:20378608
    reference_title: Gene therapy rescues cone function in congenital achromatopsia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: restoration of cone function and day vision in two canine models of CNGB3 achromatopsia
    explanation: Documents functional rescue in the canine model.
diagnosis:
- name: Electroretinography
  description: >-
    Full-field electroretinography is the decisive test. Cone dystrophy shows a
    photopic-selective deficit with markedly reduced light-adapted single-flash
    and near-extinguished 30 Hz flicker responses, while scotopic rod responses
    remain relatively preserved.
  diagnosis_term:
    preferred_term: electroretinography
    term:
      id: NCIT:C156778
      label: Vision Assessment
  evidence:
  - reference: PMID:42525358
    reference_title: "Progressive cone dystrophy in PDE6C-associated achromatopsia with a likely pathogenic variant and a VUS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ffERG showed severe cone dysfunction, characterized by markedly reduced light-adapted
      single-flash responses and near-extinguished 30 Hz flicker responses, with relatively
      preserved rod-mediated scotopic responses.
    explanation: States the photopic-selective electroretinographic pattern that establishes
      the diagnosis.
- name: Molecular genetic testing
  description: >-
    Gene-panel or exome sequencing establishes the molecular diagnosis and is
    required for eligibility for genotype-directed therapy. Diagnostic yield is
    comparatively low in this phenotype, reflecting extensive genetic
    heterogeneity and variants such as those in the repetitive RPGR-ORF15 region
    that are hard to detect with short-read sequencing.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:40571344
    reference_title: "Characterisation and prevalence of inherited retinal diseases in the Finnish population reveals enrichment of population-specific phenotypes and causative variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The lowest rates of causative variant identification were observed in cone or
      cone-rod dystrophy and macular dystrophy.
    explanation: Documents the comparatively low molecular diagnostic yield in this phenotype.
treatments:
- name: Supportive Low-Vision Management
  description: >-
    No approved cure exists. Management is supportive: tinted and edge-filter
    lenses for photophobia, refractive correction, low-vision aids, and genetic
    counselling.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Progressive Central Vision Loss
    treatment_effect: MODULATES
    description: >-
      Optical and low-vision measures mitigate the functional consequences of
      central cone loss without altering the degeneration itself.
    evidence:
    - reference: PMID:40736814
      reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients usually present with decreased central vision and a color vision
        deficit; the visual loss is progressive and often accompanied by day blindness (hemeralopia)
        and light intolerance (photophobia).
      explanation: Names the symptom burden - photophobia, day blindness and central acuity
        loss - that optical and low-vision measures address.
  evidence:
  - reference: PMID:40736814
    reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Visual acuity deteriorates to 20/200 or even counting fingers.
    explanation: The degree of acuity loss that makes low-vision rehabilitation the mainstay
      of management.
- name: AAV Gene Supplementation
  description: >-
    Experimental, and the most advanced therapeutic frontier. Subretinal AAV
    delivery of the wild-type gene restored cone function and day vision in canine
    CNGB3 achromatopsia, providing the proof of concept for recessive
    loss-of-function cone disease. Dominant gain-of-function GUCY2D disease is not
    addressable by supplementation alone and requires editing approaches.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Cone CNG Channel Loss of Function
    treatment_effect: RESTORES
    description: >-
      Supplying a functional copy of CNGA3 or CNGB3 restores the cone dark current
      and with it cone phototransduction. This is the arm the approved-trial gene
      therapies address; the cGMP-elevating arms are not corrected by
      supplementation.
    evidence:
    - reference: PMID:20378608
      reference_title: Gene therapy rescues cone function in congenital achromatopsia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: restoration of cone function and day vision in two canine models of CNGB3
        achromatopsia
      explanation: Demonstrates restoration of the failed cone pathway by gene supplementation.
  evidence:
  - reference: PMID:20378608
    reference_title: Gene therapy rescues cone function in congenital achromatopsia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: rAAV-mediated gene replacement therapy with different forms of the human red
      cone opsin promoter led to the restoration of cone function and day vision in two canine
      models of CNGB3 achromatopsia
    explanation: Documents the AAV construct and the functional rescue achieved in the
      preclinical model.
  - reference: PMID:42542214
    reference_title: 'The efficacy and safety of adeno-associated virus-mediated gene therapy
      for CNGA3- and CNGB3-associated achromatopsia: A genotype-aware systematic review and
      meta-analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pooled analysis showed modest, but statistically significant, improvement in best-corrected
      visual acuity, with a mean difference of 2.65 ETDRS letters, and significant improvement
      in contrast sensitivity.
    explanation: Pools nine human trials; the benefit is real but modest, which is why this
      is recorded as PARTIAL rather than full support for clinical efficacy.
progression:
- phase: Onset and diagnosis
  age_range: Mid-teenage years or later in most progressive forms; before 12 years in
    KCNV2 disease
  notes: >-
    Presentation is usually with declining central acuity, colour vision loss and
    photophobia. Diagnosis follows the photopic-selective electroretinogram.
    Early-onset forms such as KCNV2 disease present considerably sooner.
  evidence:
  - reference: PMID:40736814
    reference_title: Progressive Cone Dystrophy and Cone-Rod Dystrophy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A heterogenous group of diseases, progressive cone dystrophy usually begins in
      the mid-teenage years or later in life.
    explanation: States the onset window for typical progressive disease.
  - reference: PMID:33309813
    reference_title: 'KCNV2-Associated Retinopathy: Genetics, Electrophysiology, and Clinical
      Course-KCNV2 Study Group Report 1.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients were symptomatic before 12 years of age (range, 0-11 years).
    explanation: Documents the much earlier onset of the KCNV2 subtype, which the age range
      brackets.
- phase: Progressive central sensitivity loss
  notes: >-
    Central retinal sensitivity declines faster in the cone-rod phenotype than in
    rod-cone disease, giving a shorter interval to total central sensitivity loss.
    The disease is lifelong and legally blinding but not directly life-limiting.
  evidence:
  - reference: PMID:41237986
    reference_title: Central Retinal Sensitivity Decline in RPGR-Related Retinal Phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The median survival age to total loss of sensitivity for MS16 was 25.1 years
      in CORD and 33.1 years in rod-cone
    explanation: Gives the interval to total central sensitivity loss, the long-term
      functional endpoint.
disease_term:
  preferred_term: cone dystrophy
  term:
    id: MONDO:0000455
    label: cone dystrophy
notes: >-
  Scope: this entry covers progressive cone dystrophy and, where rods become
  secondarily involved, cone-rod dystrophy, which MONDO and the clinical
  literature treat as a continuum rather than separate diseases. It is distinct
  from Achromatopsia, already curated, which is congenital and stationary rather
  than progressive.

  The pathograph is organised around the convergent cGMP/calcium node rather than
  by gene, because dominant GUCA1A and GUCY2D gain-of-function alleles and
  recessive PDE6C loss-of-function alleles reach the same biochemical lesion from
  opposite directions. Recessive CNGA3/CNGB3 channel loss does not feed that node
  and is modelled as a separate arm, for the reason set out below. The X-linked RPGR arm is modelled
  separately because it acts through a glutamylation and trafficking defect, not
  through cGMP.

  Direction of the CNG channel arm: an earlier draft of this entry routed
  CNGA3/CNGB3 loss into cGMP elevation alongside PDE6C loss. That is wrong. The
  channel reads the cGMP signal rather than degrading it, so its loss removes the
  dark current and leaves cones hyperpolarised with low rather than elevated
  outer-segment calcium. PMID:35327647 shows Cngb1-null animals are partially
  protected from degeneration, confirming the channel is downstream of cGMP on the
  calcium-death route rather than upstream of it. The two recessive arms are
  therefore modelled separately and only the phosphodiesterase arm feeds the cGMP
  node.

  Known extension points: a datasets section; clinical_trials, including the
  Phase 1-2 CNGA3 and CNGB3 gene therapy trials; ABCA4 and CRX as additional
  genetic entries; dual-AAV ablate-and-replace editing for dominant GUCY2D
  disease; optical coherence tomography ellipsoid-zone and fundus autofluorescence
  findings as diagnostic modalities; and founder-population data for CNGA3 and
  CNGB3.

📚

References & Deep Research

Deep Research

1

OpenScientist ▸

Cone Dystrophy: A Comprehensive Disease Characteristics Report

openscientist-autonomous 36 citations 2026-08-27T20:30:15.163312

Cone Dystrophy: A Comprehensive Disease Characteristics Report

Disease: Cone Dystrophy (and Cone-Rod Dystrophy) · MONDO: MONDO:0000455 · Category: Inherited retinal dystrophy / progressive cone photoreceptor degeneration

Identifiers: MONDO:0000455 · MeSH: Cone-Rod Dystrophies · OMIM (representative): CDSRR 610356; multiple CORD/COD phenotype numbers · ICD-11: hereditary retinal dystrophy range (9B70.x) · Orphanet: cone/cone-rod dystrophy entries

Summary

Cone dystrophy (CD) is a genetically heterogeneous inherited retinal dystrophy (IRD) defined by primary dysfunction and progressive degeneration of the cone photoreceptors that populate the fovea and macula. Clinically, patients present with decreased central visual acuity, dyschromatopsia (color-vision loss), photophobia/hemeralopia (day-blindness and glare intolerance), and — in early-onset forms — nystagmus. When rod photoreceptors are secondarily involved, the disorder is termed cone-rod dystrophy (CORD), which adds nyctalopia (night blindness) and peripheral field loss to the phenotype. Estimated prevalence is approximately 1 in 30,000–40,000 for progressive cone dystrophy, making cone/cone-rod dystrophy one of the more common IRDs after retinitis pigmentosa and Stargardt disease.

Mechanistically, a large fraction of cone dystrophies converge on dysregulation of the cGMP/Ca²⁺ phototransduction node in cone outer segments. Dominant gain-of-function mutations in GUCA1A (GCAP1) and GUCY2D (retinal guanylate cyclase, RetGC-1) cause aberrantly sustained cGMP synthesis; recessive mutations in PDE6C/PDE6H (cGMP phosphodiesterase) and CNGA3/CNGB3 (cone CNG channel) disrupt the same pathway. Excess cGMP over-activates cyclic nucleotide-gated channels, producing Na⁺/Ca²⁺ influx and Ca²⁺ overload that triggers a downstream calpain/PARP cell-death cascade — a genotype-agnostic execution mechanism that is an attractive neuroprotective drug target. Other forms act through ciliary/structural trafficking defects (RPGR, RPGRIP1, CDHR1, CEP290), visual-cycle/RPE dysfunction (ABCA4), transcriptional dysregulation (CRX), or ion-channel modification (KCNV2, which produces the pathognomonic "supernormal rod" ERG of CDSRR).

Diagnosis rests on a photopic-selective ERG signature — reduced/extinguished light-adapted single-flash and 30-Hz flicker responses with relatively preserved scotopic (rod) responses — combined with SD-OCT (ellipsoid-zone/outer-retinal loss), fundus autofluorescence (central or bull's-eye maculopathy), and gene-panel/exome sequencing. No approved cure exists; management is largely supportive (tinted/edge-filter lenses, low-vision aids, refractive correction, genetic counseling). The most advanced therapeutic frontier is AAV-mediated gene supplementation for CNGA3/CNGB3 achromatopsia, which is safe and produces modest but statistically significant functional gains (pooled +2.65 ETDRS letters), with greater benefit for CNGA3 and when treatment occurs in childhood. Accurate early molecular diagnosis and genetic counseling are therefore the pivotal intervention levers.

Key Findings

1. Epidemiology: prevalence ~1:14,000–1:40,000

Cone dystrophy and cone-rod dystrophy rank among the more common inherited retinal diseases. A nationwide Israeli IRD study (n=9,396 diagnosed individuals) found cone-rod dystrophy prevalence of approximately 1:14,000, the second most common IRD after retinitis pigmentosa (~1:2,400), with Stargardt disease at ~1:16,000 and all IRDs combined at 1:1,043 (PMID: 38753338). The GeneReviews-level estimate for progressive cone dystrophy specifically is 1 in 30,000–40,000 (PMID: 40736814).

A notable feature is the comparatively low genetic diagnostic yield for cone/cone-rod dystrophy relative to other IRD subphenotypes. In a Finnish cohort, "the lowest rates of causative variant identification were observed in cone or cone-rod dystrophy and macular dystrophy" (PMID: 40571344), reflecting the extensive genetic heterogeneity and the existence of causative variants (e.g., in the repetitive RPGR-ORF15 region) that are difficult to detect with standard short-read sequencing.

2. Core pathophysiology: dysregulated cGMP/Ca²⁺ phototransduction

The unifying molecular theme across many cone dystrophies is disruption of the cGMP/Ca²⁺ second-messenger cycle in cone photoreceptors. In dominant disease, GCAP1 (GUCA1A) mutations in the EF-hand Ca²⁺-binding motifs (e.g., L151F in EF4, Y99C, E111A) reduce Ca²⁺ affinity so that GCAP1 fails to switch off retinal guanylate cyclase (RetGC-1/GUCY2D) at the high Ca²⁺ concentrations found in dark-adapted photoreceptors. Enzymatic work showed that "GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely inhibited at high physiological [Ca²⁺], consistent with a lowered affinity for Ca²⁺-binding to EF4" (PMID: 15790869).

Analogously, GUCY2D mutations at the dimerization domain (R838C/R838S; CORD6) act as dominant gain-of-function alleles: the R838C substitution "increases the apparent affinity of RetGC-1 for GCAP-1 and alters the Ca²⁺ sensitivity of the GCAP-1 response, allowing the mutant to be stimulated by GCAP-1 at higher Ca²⁺ concentrations than wild type" (PMID: 10430891). Both mechanisms produce persistent cyclase stimulation and cGMP overproduction. Recessive PDE6C/PDE6H (which degrade cGMP) and CNGA3/CNGB3 (the cone CNG channel) disrupt the same node from the opposite direction. Elevated cGMP and consequent Ca²⁺ influx is cytotoxic, driving cone (then rod) degeneration.

3. Diagnostic signature: photopic-selective ERG deficit

The hallmark electrophysiologic finding is a cone-selective (photopic) ERG deficit with preserved rod (scotopic) responses. Genetically confirmed cone dystrophy cases show "severe cone dysfunction, characterized by markedly reduced light-adapted single-flash responses and near-extinguished 30 Hz flicker responses, with relatively preserved rod-mediated scotopic responses" (PMID: 42525358). SD-OCT shows foveal ellipsoid-zone attenuation/loss with relative RPE preservation early in disease, and FAF shows central or bull's-eye abnormality.

A special case is KCNV2/CDSRR, which shows a pathognomonic delayed "supernormal" rod b-wave with a squared a-wave: "the ERG showed a delayed and supernormal b-wave with a 'squaring (trough-flattened)' a-wave in the DA-30 ERG, and CDSRR was diagnosed" (PMID: 38630375).

4. Natural history and prognosis: progressive central vision loss; EZ length as an early biomarker

Cone and cone-rod dystrophies follow a chronic, progressive course centered on the macula. In an RPGR cohort (n=50; 357 microperimetry assessments), cone-rod dystrophy central sensitivity declined faster than rod-cone disease: 10.8%/yr (MS16) and 14.9%/yr (MS4) in CORD versus 5.1% and 4.1%/yr in rod-cone (P=.02 and P<.001), with median survival age to total central sensitivity loss of 25.1 years (CORD) vs 33.1 years (rod-cone) (PMID: 41237986).

Structural biomarkers precede functional decline. In autosomal recessive PROM1 IRD (n=6, median 11.8-year follow-up), "best-corrected visual acuity (BCVA) was maintained until a steep decline around 15 years of age. This was preceded by contraction of the subfoveal ellipsoid zone length (EZL), measured on OCT" (PMID: 40494823). Disease is lifelong/chronic and legally blinding but not directly life-limiting; onset in most progressive cone dystrophies is in the first-to-third decade.

5. RPGR-ORF15 glutamylation defect drives X-linked cone/cone-rod dystrophy

X-linked cone dystrophy caused by RPGR involves a post-translational modification defect. TTLL5 glutamylates RPGR-ORF15 in its Glu-Gly-rich repeat region; loss of this modification causes photoreceptor degeneration. The "Ttll5 mutant mouse develops slow photoreceptor degeneration with early mislocalization of cone opsins, features resembling those of Rpgr-null mice" (PMID: 27162334). Distal truncating RPGR-ORF15 variants that impair glutamylation associate with a cone-dominated phenotype: "impaired glutamylation caused by distal truncating variants in RPGR ORF15 and its association with the cone-dominated phenotype have provided the first molecular evidence of a genotype-phenotype correlation" (PMID: 41481301).

6. Treatment landscape: no approved cure; AAV gene supplementation and CRISPR

No approved pharmacologic cure exists. Management is supportive (tinted/edge-filter glasses and photochromic lenses for photophobia, refractive correction, low-vision aids, UV protection, genetic counseling). The most advanced therapeutic is AAV subretinal gene supplementation for recessive disease: "rAAV-mediated gene replacement therapy with different forms of the human red cone opsin promoter led to the restoration of cone function and day vision in two canine models of CNGB3 achromatopsia" (PMID: 20378608).

For autosomal-dominant gain-of-function GUCY2D CORD, simple gene supplementation is insufficient; editing strategies are required. A dual-AAV "ablate-and-replace" (AAV-SaCas9) approach "preserved outer nuclear layer thickness for up to 24 weeks" in mice, whereas ablation alone did not restore function (PMID: 42264060).

7. Downstream cell-death cascade: cGMP → CNG channel → Ca²⁺ → calpain/PARP

Elevated photoreceptor cGMP over-activates CNG channels, causing Na⁺/Ca²⁺ influx, membrane depolarization, and Ca²⁺ overload that triggers excessive activation of calpain proteases and poly(ADP-ribose) polymerase (PARP), executing photoreceptor death. This pathway is druggable: cGMP accumulation is "associated with the excessive activation of calpain and poly (ADP-ribose) polymerase (PARP). Inhibitors of calpain or PARP have shown promise in preventing photoreceptor cell death" (PMID: 35327647).

Some CNG channel variants classically labeled loss-of-function are in fact gain-of-function: "CNGA3_R410W/CNGB3 and TAX4_R421W channels are spontaneously active without cGMP and induce cell death, suggesting cone degeneration triggered by spontaneous CNG channel activity as a possible cause of achromatopsia" (PMID: 35233102).

8. Phenotype spectrum and symptom frequencies

In the KCNV2 Study Group cohort (n=117), mean age of onset was 3.9 years and all patients were symptomatic before 12 years. Decreased visual acuity was present in 100%; reduced color vision in 78.6%; photophobia in 53.5%; nyctalopia in 43.6%; and nystagmus in 38.6% (PMID: 33309813). A genetically confirmed achromatopsia cohort (n=21) found that all patients had color-vision difficulty, 20/21 (95.2%) had photosensitivity, 18/21 (85.7%) had congenital nystagmus, and one-third had nyctalopia (PMID: 41867372).

Symptom / Sign	KCNV2 cohort (n=117)	ACHM cohort (n=21)	HPO term
Decreased visual acuity	100%	—	HP:0007663 (reduced visual acuity)
Reduced color vision / dyschromatopsia	78.6%	100%	HP:0000551 (abnormality of color vision)
Photophobia / photosensitivity	53.5%	95.2%	HP:0000613
Nyctalopia (night blindness)	43.6%	~33%	HP:0000662
Nystagmus	38.6%	85.7%	HP:0000639

9. Genetic heterogeneity, allelism, and syndromic differential diagnosis

The same gene often produces a phenotypic continuum. CNGA3/CNGB3 cause both stationary achromatopsia and progressive cone/cone-rod dystrophy: "In rare cases, variants in CNGA3 are also associated with cone dystrophy, Leber's congenital amaurosis and oligo cone trichromacy" (PMID: 25052312). GUCY2D underlies both recessive Leber congenital amaurosis and dominant CORD6.

Syndromic cone-rod dystrophy occurs in Alström syndrome (ALMS1), where "age of symptom onset (i.e. nystagmus and photophobia) was at 6-9 months in all patients. These symptoms mostly mislead to the diagnosis of congenital achromatopsia (ACHM), Leber congenital amaurosis (LCA), isolated CORD or Bardet-Biedl syndrome" (PMID: 29193673); as well as Bardet-Biedl syndrome (BBS1) and Spinocerebellar ataxia type 7. Non-syndromic causal genes span phototransduction (GUCA1A, GUCY2D, PDE6C, PDE6H, CNGA3, CNGB3, GNAT2, KCNV2), visual cycle/RPE (ABCA4, RPGR), transcription factors (CRX), and ciliary/structural/trafficking genes (RPGRIP1, RIMS1, RAB28, C8orf37, POC1B, TTLL5, CDHR1, PROM1, RP1L1, CEP290, ADAM9, UNC119).

10. Inheritance, founder effects, and consanguinity

Inheritance is autosomal dominant (GUCA1A, GUCY2D/CORD6, some CRX, RIMS1, PROM1, AIPL1), autosomal recessive (CNGA3, CNGB3, PDE6C, PDE6H, ABCA4, RPGRIP1, CDHR1, C8orf37, POC1B, RAB28, ADAM9, CERKL, etc.), or X-linked (RPGR/COD1, CACNA1F). Recessive forms are enriched by consanguinity and founder effects: "Two CNGA3 founder mutations underlie >50% of cases. These mutations lead to a high ACHM prevalence of ∼1:5000 among Arab-Muslims residing in Jerusalem" (PMID: 25616768) — versus ~1:30,000 generally. In Newfoundland, "recurrent mutations p.T383fsX and p.L527R were due to a founder effect" (PMID: 23362848). The CNGB3 founder allele is also famous in the Pingelapese ("island of the colorblind"). Dominant GUCA1A/GUCY2D disease shows variable expressivity and incomplete/age-dependent penetrance; X-linked RPGR shows variable manifestation in female carriers.

11. Diagnostic imaging pattern (OCT/FAF)

Full-field ERG shows reduced/extinguished photopic responses with preserved scotopic responses. In a genetically confirmed cohort (n=21), "most patients [had] a normal scotopic response and absent photopic response on electroretinogram, macular hyperfluorescence on fundus autofluorescence, and normal optical coherence tomography imaging" (PMID: 41867372). Adult-onset CD/CRD frequently shows "a bull's eye pattern with foveal sparing, consistent with perifoveal photoreceptor loss on optical coherence tomography" (PMID: 38091967). SD-OCT documents "loss of the ellipsoid zone line and collapse of the outer nuclear segment" with extinguished photopic ERG (PMID: 39100576).

12. AAV gene therapy for CNGA3/CNGB3 achromatopsia

A genotype-aware systematic review/meta-analysis of 9 human AAV gene therapy studies found: "Pooled analysis showed modest, but statistically significant, improvement in best-corrected visual acuity, with a mean difference of 2.65 ETDRS letters, and significant improvement in contrast sensitivity. Retinal sensitivity did not improve significantly, whereas color discrimination showed small but significant improvement" (PMID: 42542214). The same analysis found an "approximate adverse-event probability of 29%, with events generally mild, transient, and manageable." Benefit is mainly in CNGA3, with a non-linear dose response. Achromatopsia is a leading gene-therapy target because "Up to 80% of the patients carry mutations in the genes CNGA3 and CNGB3 encoding the two subunits of the cone cyclic nucleotide-gated channel" (PMID: 28095637). Treating in childhood may restore temporal resolution, with flicker-fusion approaching control levels only in a treated child (PMID: 42602306).

13. Animal and cellular models

Naturally occurring and engineered models recapitulate the disease across species. "Naturally occurring mouse models with mutations in Cnga3 (cpfl5 mice) and Gnat2 (cpfl3 mice) were discovered at The Jackson Laboratory. A natural occurring canine model with CNGB3 mutations has also been found" (PMID: 20238068). The Cdhr1 knockout recapitulates shortened/disorganised photoreceptor outer segments and is rescued by gene therapy: "AAV gene supplementation therapy delivered by subretinal injection can lead to long-term morphological, structural, functional and behavioural improvements in the Cdhr1 knockout mouse model... CDHR1 supplementation restored full-length photoreceptor outer segments" (PMID: 42562233). The canine RPGRIP1 cord1 model in English Springer Spaniels shows "insidious pathology with delayed-onset visual defects" (PMID: 39428496) — a naturally occurring large-animal model. Patient-derived iPSC/retinal organoids (e.g., for KCNV2, CEP290) are also established.

14. KCNV2/CDSRR: a distinct subtype

Biallelic KCNV2 (Kv8.2) variants cause "cone dystrophy with nyctalopia and supernormal rod responses" (CDSRR; OMIM 610356), autosomal recessive, "featuring pathognomonic findings on electroretinography (ERG)" (PMID: 38630375). Kv8.2 co-assembles with Kv2.1 in photoreceptor inner segments; mouse Kcnv2 knockouts model the disorder.

15. Anatomical structures affected

Cone dystrophy primarily affects the neural retina — cone photoreceptors of the fovea centralis within the macula: "Fovea centralis, located at the center of the macula, is packed with cone photoreceptors and is responsible for central visual acuity" (PMID: 36934831). SD-OCT localizes pathology to the outer retinal bands: in CORD (n=24 eyes), "A ring maculopathy appearance involving the fovea area was observed in all study eyes. There was an absence of interdigitation zone in the entire length of SD-OCT scan, including the foveal area, in all 24 study eyes" (PMID: 23648999). The RPE becomes secondarily involved as disease advances; involvement is bilateral.

Section-by-Section Synthesis (Research Template)

1. Disease Information

Cone dystrophy is an inherited retinal dystrophy of primary cone photoreceptor dysfunction/degeneration, distinguished from retinitis pigmentosa (a rod-cone disorder) by its cone-first pathology. It is classified along two axes: (i) course — stationary/congenital cone dysfunction syndromes (achromatopsia, blue-cone monochromatism) vs progressive cone dystrophy; and (ii) rod involvement — pure cone dystrophy vs cone-rod dystrophy (CORD; primary cone loss with secondary rod degeneration): "Cone and cone-rod dystrophies can be divided according to the disease course into stationary and progressive disorders or by the genetic mode of inheritance into autosomal-recessive, autosomal-dominant, and X-linked traits" (PMID: 19184602). Identifiers: MONDO:0000455; OMIM CDSRR 610356 and multiple CORD entries; MeSH "Cone-Rod Dystrophies"; Orphanet cone/cone-rod dystrophy entries; ICD-11 9B70-range. Synonyms: progressive cone dystrophy, cone-rod dystrophy (CORD/CoRD), COD. Information is drawn from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) and cohort/registry studies, not single-patient EHR (PMID: 40736814).

2. Etiology

Cone dystrophy is a Mendelian genetic disorder; there are no established environmental or infectious causes. Causal factors are pathogenic variants in ≥20 genes (see Section 4). Genetic risk is defined by the causal variant and inheritance mode; consanguinity and founder effects are the dominant population-level risk amplifiers for recessive forms (PMID: 25616768, PMID: 23362848). No robust environmental protective factors are established; UV protection and light avoidance are symptomatic rather than disease-modifying. Gene-environment interactions are minimal for this monogenic disorder, though light exposure may modulate the rate of cGMP/CNG-driven photoreceptor stress.

3. Phenotypes

Core phenotypes are reduced central visual acuity (HP:0007663), dyschromatopsia (HP:0000551), photophobia (HP:0000613), nyctalopia in cone-rod forms (HP:0000662), nystagmus in early-onset forms (HP:0000639), and central/paracentral scotoma (visual field defect, HP:0001123). Frequencies are quantified in Finding 8. Onset ranges from infancy (syndromic/achromatopsia-overlap forms, <1 year) to mid-teens/adulthood (progressive cone dystrophy). Severity is variable and progression is typically slow but relentless, ending in legal blindness (20/200 or worse). Quality-of-life impact centers on loss of reading/central vision, disabling glare, and color-discrimination failure; formal per-phenotype QOL instruments are underused in this population.

4. Genetic/Molecular Information

Causal genes by functional class: phototransduction — GUCA1A, GUCY2D, PDE6C, PDE6H, CNGA3, CNGB3, GNAT2, KCNV2; visual cycle/RPE — ABCA4, RPGR; transcription — CRX; ciliary/structural/trafficking — RPGRIP1, RIMS1, RAB28, C8orf37, POC1B, TTLL5, CDHR1, PROM1, RP1L1, CEP290, ADAM9, UNC119. Variant types include missense (e.g., GUCA1A L151F/Y99C, GUCY2D R838C/S, CNGA3 p.Cys319Arg), frameshift (CNGB3 p.T383fs), nonsense/truncating (RPGR-ORF15 distal truncations), and structural variants. Functional consequences are gain-of-function for dominant GUCA1A/GUCY2D (sustained cGMP synthesis) and for certain CNG variants (constitutive channel opening; PMID: 35233102); loss-of-function for most recessive alleles. Modifier genes: KCNV2 itself acts as a channel modifier subunit; TTLL5 modifies RPGR via glutamylation. Epigenetic and large-scale chromosomal abnormalities are not major contributors, though structural variants at loci such as RP17/CEP290 require careful classification (PMID: 42545071).

5. Environmental Information

Not applicable as primary cause — cone dystrophy is monogenic. No toxins, radiation, lifestyle factors, or infectious agents are established causes. Bright-light exposure and lack of UV/glare protection worsen symptoms but do not initiate disease.

6. Mechanism/Pathophysiology

The dominant pathway is cGMP/Ca²⁺ dysregulation → CNG-channel over-activation → Ca²⁺ overload → calpain/PARP-mediated photoreceptor death (see Mechanistic Model below). Relevant GO biological processes: phototransduction (GO:0007602), cGMP metabolic process (GO:0046068), regulation of cytosolic calcium ion concentration (GO:0051480), photoreceptor cell maintenance (GO:0045494), neuron apoptotic process (GO:0051402). GO cellular components: photoreceptor outer segment (GO:0001750), photoreceptor connecting cilium (GO:0032391), cyclic nucleotide-gated ion channel complex. Cell type (CL): retinal cone cell (CL:0000573). Additional mechanisms include ciliary transport defects (RPGR/RPGRIP1/CEP290), outer-segment structural failure (CDHR1), visual-cycle toxicity (ABCA4 lipofuscin/bisretinoid accumulation), and transcriptional dysregulation (CRX).

7. Anatomical Structures Affected

Primary: cone photoreceptors of the fovea centralis (UBERON:0001786 fovea centralis) within the macula lutea (UBERON:0005388), in the neural retina (UBERON:0003902). Outer-retinal bands affected on OCT: external limiting membrane, ellipsoid zone (IS/OS), interdigitation zone, and secondarily the retinal pigment epithelium (UBERON:0001782). Subcellular: photoreceptor outer segment and connecting cilium. Body system: nervous/visual system. Involvement is bilateral (PMID: 23648999, PMID: 36934831).

8. Temporal Development

Onset is bimodal: infancy/early childhood for achromatopsia-overlap and syndromic forms (mean 3.9 years in KCNV2; PMID: 33309813), and mid-teens/adulthood for classic progressive cone dystrophy. Onset pattern is insidious/chronic. Progression is generally slow but relentless; CORD progresses faster centrally than rod-cone disease (10.8%/yr vs 5.1%/yr; PMID: 41237986). Disease course is progressive and lifelong; there is no spontaneous remission. Ellipsoid-zone contraction marks a critical structural window preceding acuity collapse (PMID: 40494823).

9. Inheritance and Population

Prevalence ~1:30,000–40,000 (progressive CD) to ~1:14,000 (CORD in Israel) (PMID: 40736814, PMID: 38753338). Inheritance is AD, AR, or X-linked. Penetrance is complete for most recessive forms but may be incomplete/age-dependent for dominant GUCA1A/GUCY2D. Founder effects and consanguinity elevate local prevalence markedly (ACHM ~1:5,000 in Arab-Muslim Jerusalem; PMID: 25616768). Sex ratio is roughly equal for autosomal forms; X-linked RPGR disease predominantly affects males with variable female-carrier manifestation.

10. Diagnostics

Diagnosis integrates full-field ERG (photopic-selective loss; pathognomonic supernormal-rod ERG in CDSRR), SD-OCT (ellipsoid-zone/outer-nuclear-layer loss, bull's-eye maculopathy), fundus autofluorescence (central/ring hyperfluorescence), color-vision testing, and molecular genetic testing (gene panels, WES, and — for RPGR-ORF15 — long-read sequencing). Differential diagnosis includes Stargardt disease (ABCA4), occult macular dystrophy, hydroxychloroquine toxicity, and syndromic CORD (Alström, Bardet-Biedl). Because ABCA4 disease alleles are common in the population, overlap with Stargardt disease is frequent — "Fourteen probands (35%) were found to have a potentially disease-causing ABCA4 sequence variant on at least one allele" in a bull's-eye maculopathy series (PMID: 18024811). Genetic diagnostic yield is comparatively low, arguing for comprehensive/long-read approaches (PMID: 40571344, PMID: 42525358, PMID: 38091967).

11. Outcome/Prognosis

Cone dystrophy is not life-limiting; mortality is unaffected. Morbidity is defined by progressive central-vision loss to legal blindness (20/200 or worse, sometimes counting fingers), disabling photophobia, and eventual peripheral field loss in cone-rod forms (PMID: 40736814). Prognostic factors include genotype, age of onset, and structural biomarkers (ellipsoid-zone length). Recovery is not spontaneous; gene therapy offers partial, genotype-specific functional stabilization/gain in select forms.

12. Treatment

No approved cure. Supportive: tinted/red-filter and photochromic lenses, refractive correction, low-vision aids, UV protection (NCIT: supportive care; low vision aids). Advanced: AAV gene supplementation for CNGA3/CNGB3 achromatopsia (safe, +2.65 ETDRS letters pooled; PMID: 42542214); CRISPR "ablate-and-replace" for dominant GUCY2D CORD (PMID: 42264060); genotype-agnostic neuroprotection via calpain/PARP inhibitors (preclinical; PMID: 35327647). Pediatric CNGA3/CNGB3 trials are in Phases 1–2 (PMID: 42627399). NCIT terms: Gene Therapy (NCIT:C15254), Adeno-associated Virus Vector, Supportive Care (NCIT:C15274).

13. Prevention

Classical primary prevention (vaccination/lifestyle) is not applicable. Prevention is reproductive/genetic: carrier and cascade testing (high-yield in founder/consanguineous populations), preimplantation and prenatal genetic diagnosis, and genetic counseling. "Accurate diagnosis is essential for accessing emerging gene-targeted treatments for inherited retinal diseases (IRDs), but many minoritised communities face additional barriers to diagnosis" (PMID: 40513990). Tertiary prevention is supportive management to preserve residual function and quality of life.

14. Other Species / Natural Disease

Naturally occurring cone/cone-rod disease is well documented in dogs (NCBI Taxon 9615): CNGB3 day-blind dogs (Alaskan Malamute, German Shorthaired Pointer) and RPGRIP1 cord1 progressive retinal atrophy in English Springer Spaniels (PMID: 39428496). Orthologous genes (Cnga3, Cngb3, Gnat2, Rpgr, Rpgrip1, Cdhr1) are conserved across mouse (NCBI Taxon 10090) and dog, enabling comparative pathology and gene-therapy proof-of-concept. Disease mechanisms are evolutionarily conserved across mammals; no zoonotic potential (non-infectious).

15. Model Organisms

Mouse: Cnga3 (cpfl5), Gnat2 (cpfl3), Cngb3 knockout, Pde6c (cpfl1), Ttll5-mutant, Rpgr-null, Cdhr1 knockout, Kcnv2 knockout, and CRX-mutant CORD models (PMID: 20238068, PMID: 27162334, PMID: 42562233). Dog: natural CNGB3 and RPGRIP1 models. Cellular: patient-derived iPSC and retinal organoids (KCNV2, CEP290). Models faithfully reproduce absent photopic ERG, day-blindness, photophobia, and cone-opsin mislocalization; limitations include species differences in macular/foveal structure (mice lack a fovea), which constrains modeling of human central-vision phenotypes. Resources: MGI, IMPC, IMSR (mouse); OMIA (dog); Cellosaurus (cell lines).

Mechanistic Model / Interpretation

The central pathophysiologic engine of many cone dystrophies is a cGMP/Ca²⁺ imbalance in the cone outer segment that converges on a common execution pathway:

   UPSTREAM (genotype-specific triggers)
   ┌─────────────────────────────────────────────────────────┐
   │  GUCA1A (GCAP1) gain-of-function ─┐                       │
   │  GUCY2D (RetGC-1) gain-of-function├─► ↑ cGMP synthesis    │
   │  PDE6C / PDE6H loss-of-function ──┘   (impaired breakdown)│
   └─────────────────────────────────────────────────────────┘
          │
          ▼
    ┌──────────────────────────────┐
    │   ELEVATED cGMP in cone OS    │
    └──────────────────────────────┘
          │
┌─────────────────┴───────────────────┐
▼                                     ▼
  Over-activation of                Constitutive CNG opening
  CNGA3/CNGB3 channels              (gain-of-function variants,
  (excess ligand)                    e.g. CNGA3 R410W)
└─────────────────┬───────────────────┘
          ▼
    ┌──────────────────────────────┐
    │  Na⁺/Ca²⁺ INFLUX → Ca²⁺       │
    │  OVERLOAD + depolarization    │
    └──────────────────────────────┘
          │
          ▼
   DOWNSTREAM (genotype-agnostic executioner)
    ┌──────────────────────────────┐
    │  Calpain + PARP activation    │  ◄── DRUGGABLE
    │  → photoreceptor cell death   │      NODE
    └──────────────────────────────┘
          │
          ▼
   CLINICAL MANIFESTATION
   Cone loss → ↓ acuity, dyschromatopsia, photophobia
   (± secondary rod loss → nyctalopia, peripheral field loss = CORD)

Parallel/alternative mechanisms feed into the same end-stage cone death without traversing the cGMP node:

Mechanism class	Representative genes	Effect
cGMP/Ca²⁺ dysregulation	GUCA1A, GUCY2D, PDE6C/H, CNGA3/B3	↑cGMP → CNG over-activation → Ca²⁺ death cascade
Ciliary/OS transport	RPGR, RPGRIP1, CEP290, TTLL5	Opsin mislocalization, cilium dysfunction
Outer-segment structure	CDHR1, PROM1	Shortened/disorganized OS, failed disc morphogenesis
Visual cycle / RPE	ABCA4	Bisretinoid/lipofuscin toxicity
Transcription	CRX	Failed photoreceptor gene expression/maintenance
Ion-channel modifier	KCNV2 (Kv8.2)	Altered inner-segment K⁺ handling (CDSRR, supernormal rod ERG)

The calpain/PARP node is genotype-agnostic, making it the most attractive target for a broadly applicable neuroprotective small-molecule therapy, complementary to gene-specific AAV/CRISPR approaches. Upstream, gain-of-function dominant disease (GUCA1A/GUCY2D and certain CNG variants) requires silencing/editing rather than simple supplementation, explaining why "ablate-and-replace" strategies are needed for CORD6.

Evidence Base

PMID	Title (abbrev.)	Supports finding
38753338	Nationwide IRD prevalence, Israel	Epidemiology (CORD ~1:14,000)
40736814	Progressive Cone & Cone-Rod Dystrophy (GeneReviews)	Prevalence ~1:30–40k, onset, prognosis
40571344	Finnish IRD prevalence	Low diagnostic yield in CD/CRD
15790869	GCAP1 L151F adCORD	GUCA1A gain-of-function mechanism
10430891	RetGC-1 dimerization mutation	GUCY2D R838C gain-of-function
42525358	PDE6C progressive cone dystrophy	Photopic-selective ERG signature
38630375	KCNV2 siblings	Pathognomonic CDSRR ERG
41237986	RPGR central sensitivity decline	CORD faster central decline
40494823	PROM1 longitudinal study	EZ length as early biomarker
27162334	TTLL5/RPGR glutamylation	X-linked cone dystrophy mechanism
41481301	RPGR-ORF15 female carriers	Genotype-phenotype correlation
20378608	Gene therapy in canine CNGB3	AAV restores cone function
42264060	CRISPR for CORD/ACHM	Ablate-and-replace for dominant GUCY2D
35327647	PARP/calpain in IRD	cGMP death cascade & druggability
35233102	ACHM channel mutation	CNG gain-of-function
33309813	KCNV2 Study Group	Symptom frequencies
41867372	Achromatopsia cohort	Phenotype frequencies, imaging
25052312	CNGA3 cone-rod dystrophy	Allelic continuum
29193673	ALMS1 cone-rod dystrophy	Syndromic differential
25616768	CNGA3 achromatopsia genetics	Founder effect, elevated prevalence
23362848	Newfoundland achromatopsia	Founder effects
23648999	Outer retina OCT in CORD	Foveal/macular band pathology
36934831	Foveal photoreceptor OCT	Fovea/macula as target
42542214	AAV meta-analysis (ACHM)	Efficacy +2.65 letters, safety
28095637	Gene therapy for achromatopsia	80% CNGA3/CNGB3
20238068	Achromatopsia gene therapy candidate	Animal models
42562233	CDHR1 degeneration	Knockout model + gene therapy rescue
39428496	Canine cord1 RPGRIP1	Large-animal CORD model
18024811	ABCA4 bull's-eye maculopathy	ABCA4/Stargardt overlap
19184602	Genetics of cone/cone-rod dystrophies	Classification framework
40513990	IRD in Indigenous populations	Diagnosis as prevention lever
42627399	Pediatric gene therapy trials	CNGA3/CNGB3 trials Phase 1–2
42602306	Temporal vision in ACHM	Childhood treatment restores flicker fusion
38091967	Adult-onset CD/CRD	Bull's-eye maculopathy, presenting symptom
39100576	CORD case	OCT EZ loss + extinguished photopic ERG

How the evidence coheres: The mechanistic papers (10430891, 15790869, 35327647, 35233102) establish the cGMP→CNG→Ca²⁺→calpain/PARP causal chain; the cohort/imaging papers (42525358, 33309813, 41867372, 23648999) establish the clinical/diagnostic phenotype; the epidemiology/genetics papers (38753338, 40736814, 25616768, 23362848) establish population parameters; and the therapeutic papers (42542214, 20378608, 42264060, 42562233) establish the treatment frontier. No papers in the reviewed set directly contradict the core model, though the low diagnostic yield (40571344) and difficulty resolving RPGR-ORF15 variants flag that the known genetic spectrum is incomplete.

Limitations and Knowledge Gaps

No primary experimental dataset. This report is a literature-synthesis of published cohorts, mechanistic studies, and reviews; no independent statistical analysis of raw patient data was performed. All effect sizes and prevalence figures are as reported in the primary literature.
Genetic diagnostic gap. Cone/cone-rod dystrophy has among the lowest causative-variant identification rates of all IRD subphenotypes (PMID: 40571344). Hidden causes include structural variants, deep-intronic/pseudoexon variants (e.g., CEP290; PMID: 42545071), and the repetitive RPGR-ORF15 region that eludes short-read sequencing.
Prevalence heterogeneity. Estimates range from ~1:14,000 (CORD, Israel) to ~1:30,000–40,000 (progressive CD), reflecting differences in ascertainment, definition (cone vs cone-rod vs achromatopsia), and population structure (founder/consanguineous enrichment). A single global figure is not well established.
Therapeutic evidence is genotype-narrow. Robust human gene-therapy data exist essentially only for CNGA3/CNGB3 achromatopsia; efficacy for CNGB3 is uncertain, and dominant gain-of-function forms (GUCA1A/GUCY2D) lack approved editing therapies. Calpain/PARP neuroprotection remains preclinical.
Quality-of-life data are thin. Formal per-phenotype QOL instruments (EQ-5D, SF-36, PROMIS) are rarely applied specifically to cone dystrophy cohorts; QOL impact is inferred from functional endpoints.
Model organism limitations. Mice lack a fovea, limiting fidelity for the central-vision phenotype that dominates human disease; large-animal (dog) models better capture cone-directed pathology but are resource-intensive.
Natural-history endpoints. Sensitive, validated structural/functional endpoints (e.g., ellipsoid-zone length, microperimetry) are still being standardized for trial readiness across genotypes.

Proposed Follow-up Experiments / Actions

Deploy long-read and structural-variant-aware sequencing (e.g., nanopore RPGR-ORF15, optical genome mapping) systematically in genetically unsolved cone/cone-rod dystrophy cohorts to close the diagnostic gap and enable therapy eligibility.
Advance genotype-agnostic neuroprotection to trials. Given the convergent calpain/PARP death cascade, formally test calpain and PARP inhibitors (and CNG-channel/voltage-gated Ca²⁺/Na⁺ channel blockers) in cone-directed IRD explant and large-animal models, then early-phase human trials, as a broad add-on to gene-specific therapy.
Develop editing therapy for dominant GUCA1A/GUCY2D CORD. Optimize dual-AAV "ablate-and-replace" or base/prime-editing approaches to raise editing efficiency and durability beyond the ~24-week ONL preservation demonstrated in mice.
Standardize natural-history endpoints. Establish multicenter, genotype-stratified longitudinal cohorts using ellipsoid-zone length, microperimetry, adaptive-optics cone density, and FST as validated endpoints to power future trials.
Expand carrier/cascade screening in defined founder and consanguineous populations (e.g., Arab-Muslim Jerusalem, Pingelapese, Newfoundland) where recessive alleles are enriched, coupled with equitable access to diagnosis in underserved communities.
Extend gene-therapy age-window studies. The observation that only a treated child regained near-normal flicker-fusion argues for prospective pediatric-versus-adult comparative trials to define the critical treatment window.
Integrate patient-derived retinal organoids (iPSC) for high-throughput variant functional classification (VUS resolution) and preclinical drug screening across the diverse cone-dystrophy gene spectrum.

Report compiled from 20 confirmed findings, 10 supported hypotheses, and 94 reviewed papers across 10 investigation iterations. Evidence source types span human clinical cohorts, model organism studies (mouse, dog), in vitro/iPSC systems, and computational modeling, as annotated per citation.

Artifacts

Citations

PMID:38753338
PMID:40736814
PMID:40571344
PMID:15790869
PMID:10430891
PMID:42525358
PMID:38630375
PMID:41237986
PMID:40494823
PMID:27162334
PMID:41481301
PMID:20378608
PMID:42264060
PMID:35327647
PMID:35233102
PMID:33309813
PMID:41867372
PMID:25052312
PMID:29193673
PMID:25616768
PMID:23362848
PMID:38091967
PMID:39100576
PMID:42542214
PMID:28095637
PMID:42602306
PMID:20238068
PMID:42562233
PMID:39428496
PMID:36934831
PMID:23648999
PMID:19184602
PMID:42545071
PMID:18024811
PMID:42627399
PMID:40513990

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Animal Models

Source YAML

References & Deep Research

Deep Research

Cone Dystrophy: A Comprehensive Disease Characteristics Report

Summary

Key Findings

1. Epidemiology: prevalence ~1:14,000–1:40,000

2. Core pathophysiology: dysregulated cGMP/Ca²⁺ phototransduction

3. Diagnostic signature: photopic-selective ERG deficit

4. Natural history and prognosis: progressive central vision loss; EZ length as an early biomarker

5. RPGR-ORF15 glutamylation defect drives X-linked cone/cone-rod dystrophy

6. Treatment landscape: no approved cure; AAV gene supplementation and CRISPR

7. Downstream cell-death cascade: cGMP → CNG channel → Ca²⁺ → calpain/PARP

8. Phenotype spectrum and symptom frequencies

9. Genetic heterogeneity, allelism, and syndromic differential diagnosis

10. Inheritance, founder effects, and consanguinity

11. Diagnostic imaging pattern (OCT/FAF)

12. AAV gene therapy for CNGA3/CNGB3 achromatopsia

13. Animal and cellular models

14. KCNV2/CDSRR: a distinct subtype

15. Anatomical structures affected

Section-by-Section Synthesis (Research Template)

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism/Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

Evidence Base

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions

Artifacts

Citations